Información del artículo
La conducta clásica ante un episodio febril en un paciente neutropénico por quimioterapia ha consistido, durante años, en el ingreso hospitalario y la administración de antibioterapia empírica de amplio espectro por vía intravenosa. Sin embargo, desde finales de la década de los ochenta, se ha establecido que no todos los episodios de neutropenia comportan el mismo riesgo de complicaciones. Estos pacientes con fiebre y neutropenia de bajo riesgo, es decir, sin foco infeccioso claro, sin criterios de sepsis grave y con una duración esperada de la neutropenia inferior a 7-10 días, podrían beneficiarse de un tratamiento antibiótico ambulatorio por vía oral o, en su defecto, por vía intravenosa mediante bombas de perfusión en el propio domicilio del paciente.
En este trabajo se analiza la situación actual de estas nuevas modalidades de tratamiento, que tienen como objetivos mejorar la calidad de vida de los pacientes y optimizar los recursos y costes sanitarios.
Palabras clave:
Fiebre
Bajo riesgo
Tratamiento ambulatorio
Calidad de vida
For years the classical approach to febrile episodes in patients with chemotherapy-induced neutropenia consisted of hospital admission and intravenous administration of broad-spectrum antibiotics. However, since the end of the 1980s, it has been known that not all episodes of neutropenia carry the same risk of developing complications. These low risk febrile patients with neutropenia, that is, those without a clear focus of infection, without criteria for severe sepsis, and with an expected duration of neutropenia of less than 7-10 days, could benefit from outpatient oral antibiotic therapy or, failing this, from intravenous administration through a perfusion pump in the home.
The present study analyzes the current situation of the new treatment modalities that aim to improve patients’ quality of life and to optimize healthcare resources and costs.
Key words:
Fever
Low risk
Outpatient treatment
Quality of life
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.P. Bodey, M. Buckley, Y.S. Sathe, E.J. Freireich.
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia.
Ann Intern Med, 64 (1966), pp. 328-340
[2.]
J. Klastersky.
Management of fever in neutropenic patients with different risks of complications.
Clin Infect Dis, 39 (2004), pp. 32-37
[3.]
W.T. Hughes, D. Armstrong, G.P. Bodey, A.E. Brown, J.E. Edwards, R. Feld, et al.
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.
Clin Infect Dis, 25 (1997), pp. 551-573
[4.]
H. Ozer.
American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors.
Curr Opin Hematol, 3 (1996), pp. 3-10
[5.]
L.S. Elting, E.B. Rubenstein, K. Rolston, S.B. Cantor, C.G. Martin, D. Kurtin, et al.
Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
J Clin Oncol, 18 (2000), pp. 3699-3706
[6.]
J.A. Talcott, R. Finberg, R.J. Mayer, L. Goldman.
The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation.
Arch Intern Med, 148 (1988), pp. 2561-2568
[7.]
A. Freifeld, D. Marchigiani, T. Walsh, S. Chanock, L. Lewis, J. Hiemenz, et al.
A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
N Engl J Med, 341 (1999), pp. 305-311
[8.]
W.V. Kern, A. Cometta, R. De Bock, J. Langenaeken, M. Paesmans, H. Gaya.
Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
N Engl J Med, 341 (1999), pp. 312-318
[9.]
J.A. Talcott, R.D. Siegel, R. Finberg, L. Goldman.
Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.
J Clin Oncol, 10 (1992), pp. 316-322
[10.]
J. Klastersky, M. Paesmans, E.B. Rubenstein, M. Boyer, L. Elting, R. Feld, et al.
The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
J Clin Oncol, 18 (2000), pp. 3038-3051
[11.]
J.J. Picazo.
Management of the febrile neutropenic patient: a consensus conference.
Clin Infect Dis, 39 (2004), pp. 1-6
[12.]
J.A. García-Rodríguez, M. Gobernado, M. Gomis, J. Mensa, J. Picazo, J. Prieto, et al.
Guía clinica para la evaluación y el tratamiento del paciente neutropénico con fiebre.
Rev Esp Quimioter, 14 (2001), pp. 75-83
[13.]
H. Link, A. Bohme, O.A. Cornely, K. Hoffken, O. Kellner, W.V. Kern, et al.
Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society).
Ann Hematol, 82 (2003), pp. 105-117
[14.]
R. Ramphal.
Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.
Clin Infect Dis, 39 (2004), pp. 25-31
[15.]
L. Vidal, M. Paul, I. Ben-Dor, E. Pokroy, K. Soares-Weiser, L. Leibovici.
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.
Cochrane Database Syst Rev, (2004),
[16.]
L. Vidal, M. Paul, I. Ben dor, K. Soares-Weiser, L. Leibovici.
Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials.
J Antimicrob Chemother, 54 (2004), pp. 29-37
[17.]
E. Velasco, M.A. Costa, C.A. Martins, M. Nucci.
Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients.
Am J Clin Oncol, 18 (1995), pp. 429-435
[18.]
J.L. Shenep, P.M. Flynn, D.K. Baker, S.V. Hetherington, M.M. Hudson, W.T. Hughes, et al.
Oral cefixime is similar to continued intravenous antibiotics in the empirical treatment of febrile neutropenic children with cancer.
Clin Infect Dis, 32 (2001), pp. 36-43
[19.]
G. Samonis, E. Anaissie, K. Kalbakis.
Therapy for low-risk cancer patients with fever and enutropenia: results of a prospective, randomized trial with cost analysis [abstract LM51]. Programs and Abstracts in thirty-seventh Interscience Conference on antimicrobial Agents and Chemotherapy.
American Society of Microbiology, (1997),
[20.]
E.B. Rubenstein, K. Rolston, R.S. Benjamin, J. Loewy, C. Escalante, E. Manzullo, et al.
Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer.
Cancer, 71 (1993), pp. 3640-3646
[21.]
K. Rolston, E.B. Rubenstein, L. Elting.
Ambulatory mangement of febrile episodes in neutropenic patients. Programs and Abstracts of the Thirty-Fifth Interscinece Conference on Antimicrobial Agents and Chemotherapy [abstract LM81].
American Society for Microbiology, (1995),
[22.]
A.S. Petrilli, L.S. Dantas, M.C. Campos, C. Tanaka, V.C. Ginani, A. Seber.
Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial.
Med Pediatr Oncol, 34 (2000), pp. 87-91
[23.]
H.R. Paganini, C.M. Sarkis, M.G. De Martino, P.A. Zubizarreta, L. Casimir, C. Fernández, et al.
Oral administration of cefixime to lower risk febrile neutropenic children with cancer.
Cancer, 88 (2000), pp. 2848-2852
[24.]
C.A. Mullen, D. Petropoulos, W.M. Roberts, M. Rytting, T. Zipf, K.W. Chan, et al.
Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
Cancer, 86 (1999), pp. 126-134
[25.]
I.A. Malik, Z. Abbas, M. Karim.
Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
Lancet, 339 (1992), pp. 1092-1096
[26.]
H.E. Innes, D.B. Smith, S.M. O’Reilly, P.I. Clark, V. Kelly, E. Marshall.
Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study.
Br J Cancer, 89 (2003), pp. 43-49
[27.]
M. Hidalgo, J. Hornedo, C. Lumbreras, J.M. Trigo, R. Colomer, S. Perea, et al.
Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial.
Cancer, 85 (1999), pp. 213-219
[28.]
H. Giamarellou, H.P. Bassaris, G. Petrikkos, W. Busch, M. Voulgarelis, A. Antoniadou, et al.
Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
Antimicrob Agents Chemother, 44 (2000), pp. 3264-3271
[29.]
J.P. Flaherty, D. Waitley, B. Edlin, D. George, P. Arnow, P. O’Keefe, et al.
Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
Am J Med, 87 (1989), pp. 278S-282S
[30.]
O.A. Cornely, T. Wicke, H. Seifert, U. Bethe, M. Schwonzen, D. Reichert, et al.
Once-daily oral levofloxacin monotherapy versus piperacillin/tazobactam three times a day: a randomized controlled multicenter trial in patients with febrile neutropenia.
Int J Hematol, 79 (2004), pp. 74-78
[31.]
A. Geddes, M. Thaler, S. Schonwald, M. Harkonen, F. Jacobs, I. Nowotny.
Levofloxacin in the empirical treatment of patients with suspected bacteraemia/ sepsis: comparison with imipenem/cilastatin in an open, randomized trial.
J Antimicrob Chemother, 44 (1999), pp. 799-810
[32.]
G. Chamilos, A. Bamias, E. Efstathiou, P.M. Zorzou, E. Kastritis, E. Kostis, et al.
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
Cancer, 103 (2005), pp. 2629-2635
[33.]
F. Fernández-Avilés, E. Carreras, C. Gallego, A. Hernando, S. Segura, L. García, et al.
At-home management of pancytopenic phase after autologous stemcell transplantation (ASCT) for haematological malignancies: a single-centre experience.
Bone Marrow Transplant, 35 (2005), pp. 163
[34.]
D.N. Gilbert, R.J. Dworkin, S.R. Raber, J.E. Legget.
Outpatient parenteral antimicrobial-drug therapy.
N Engl J Med, 337 (1997), pp. 829-838
[35.]
H. Mendoza-Ruiz de Zuazu, J. Casas-Arrate, C. Martínez-Martínez, I. De la Maza, J. Regalado de Los Cobos, J.M. Cia-Ruiz.
Antibioterapia intravenosa en domicilio. Estudio de 515 casos.
Enferm Infecc Microbiol Clin, 23 (2005), pp. 396-401
[36.]
W.T. Hughes, D. Armstrong, G.P. Bodey, E.J. Bow, A.E. Brown, T. Calandra, et al.
2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.
Clin Infect Dis, 34 (2002), pp. 730-751
Copyright © 2005. Elsevier España S.L.. Todos los derechos reservados
